UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Expert review of neurotherapeutics, ISSN 1473-7175, 02/2016, Volume 16, Issue 2, pp. 131 - 144
Antidepressants | Attention Deficit Hyperactivity Disorder (ADHD) | Amphetamines | Efficacy | Lithium | Adults | Pharmacological Treatment | Metadoxine | Pharmacology & Pharmacy | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Humans | Paroxetine - therapeutic use | Venlafaxine Hydrochloride - therapeutic use | Dopamine Agents - therapeutic use | Droxidopa - therapeutic use | Pyrrolidonecarboxylic Acid - therapeutic use | Adrenergic alpha-Agonists - therapeutic use | Histamine Agents - therapeutic use | Central Nervous System Stimulants - therapeutic use | Desipramine - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Pyridoxine - therapeutic use | Adult | Lobeline - therapeutic use | Benzhydryl Compounds - therapeutic use | Nomifensine - therapeutic use | Morpholines - therapeutic use | Bupropion - therapeutic use | Pyridines - therapeutic use | Wakefulness-Promoting Agents - therapeutic use | Duloxetine Hydrochloride - therapeutic use | Guanfacine - therapeutic use | Nicotinic Agonists - therapeutic use | Attention Deficit Disorder with Hyperactivity - drug therapy | Antidepressive Agents - therapeutic use | Mecamylamine - therapeutic use | Amphetamines - therapeutic use | Lithium Compounds - therapeutic use | Lisdexamfetamine Dimesylate - therapeutic use | Nicotinic Antagonists - therapeutic use | Quinazolinones - therapeutic use | Memantine - therapeutic use | Drug Combinations | Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 03/2018, Volume 2018, Issue 3, pp. CD011481 - CD011481
Paroxetine | Pyridines | Melatonin | Pharmacological interventions | Antidepressive Agents | Aspartic Acid | Pregabalin | Substance Withdrawal Syndrome | Withholding Treatment | Otherdrug | Benzodiazepines | Carbamazepine | Homeopathy | Randomized Controlled Trials as Topic | Lithium Compounds | Sulfides | Tobacco, drugs & alcohol | Flumazenil | Imidazoles | Ethylamines | Other drugs | Buspirone | Progesterone | Medicine General & Introductory Medical Sciences | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pregabalin - therapeutic use | Humans | Carbamazepine - therapeutic use | Substance Withdrawal Syndrome - drug therapy | Sulfides - therapeutic use | Paroxetine - therapeutic use | Aspartic Acid - therapeutic use | Antidepressive Agents - therapeutic use | Progesterone - therapeutic use | Flumazenil - therapeutic use | Lithium Compounds - therapeutic use | Melatonin - therapeutic use | Adult | Benzodiazepines - administration & dosage | Benzodiazepines - adverse effects | Imidazoles - therapeutic use | Ethylamines - therapeutic use | Buspirone - therapeutic use | Pyridines - therapeutic use | Index Medicus
Journal Article
Acta psychiatrica Scandinavica, ISSN 0001-690X, 12/2014, Volume 130, Issue 6, pp. 452 - 469
antipsychotics | antidepressives | bipolar disorder | depression | Antipsychotics | Bipolar disorder | Depression | Antidepressives | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Miscellaneous | Psychology. Psychoanalysis. Psychiatry | Adult and adolescent clinical studies | Biological and medical sciences | Medical sciences | Neuropharmacology | Bipolar disorders | Psycholeptics: tranquillizer, neuroleptic | Psychopharmacology | Pharmacology. Drug treatments | Psychopathology. Psychiatry | Mood disorders | Triazines - therapeutic use | Humans | Thiazoles - therapeutic use | Aripiprazole | Depression - drug therapy | Dibenzothiazepines - therapeutic use | Lurasidone Hydrochloride | Risperidone - therapeutic use | Antipsychotic Agents - therapeutic use | Quinolones - therapeutic use | Isoindoles - therapeutic use | Adult | Valproic Acid - therapeutic use | Fluoxetine - therapeutic use | Drug Therapy, Combination | Monoamine Oxidase Inhibitors - therapeutic use | Quetiapine Fumarate | Serotonin Uptake Inhibitors - therapeutic use | Treatment Outcome | Piperazines - therapeutic use | Bipolar Disorder - drug therapy | Bipolar Disorder - psychology | Randomized Controlled Trials as Topic | Antidepressive Agents - therapeutic use | Lithium Compounds - therapeutic use | Depression - psychology | Benzodiazepines - therapeutic use | Oxidases | Olanzapine | Fluoxetine | Mania | Comparative analysis | Drug therapy | Psychotropic drugs | Psychotherapy | Mental depression | Index Medicus
Journal Article
PharmacoEconomics, ISSN 1170-7690, 9/2010, Volume 28, Issue 9, pp. 751 - 764
Quality of Life Research | Health Economics | Health Administration | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | bipolar-i-disorders, treatment | lithium, therapeutic use | aripiprazole, therapeutic use | olanzapine, therapeutic use | antipsychotics, therapeutic use | cost-utility | valproate-semisodium, therapeutic use | lamotrigine, therapeutic use | quetiapine, therapeutic use | Economics | Social Sciences | Life Sciences & Biomedicine | Health Care Sciences & Services | Pharmacology & Pharmacy | Business & Economics | Health Policy & Services | Science & Technology | Public health. Hygiene | Miscellaneous | Psychology. Psychoanalysis. Psychiatry | Adult and adolescent clinical studies | Biological and medical sciences | Medical sciences | Neuropharmacology | Bipolar disorders | Public health. Hygiene-occupational medicine | Psycholeptics: tranquillizer, neuroleptic | Psychopharmacology | Pharmacology. Drug treatments | Psychopathology. Psychiatry | Mood disorders | Piperazines - administration & dosage | Quinolones - economics | Dibenzothiazepines - economics | Lithium Compounds - economics | Markov Chains | Tablets | Triazines - therapeutic use | United States | Humans | Piperazines - economics | Risk | Absenteeism | Models, Economic | Aripiprazole | Dibenzothiazepines - therapeutic use | Antipsychotic Agents - therapeutic use | Quinolones - therapeutic use | Valproic Acid - therapeutic use | Benzodiazepines - economics | Antipsychotic Agents - economics | Hospital Charges | Quality-Adjusted Life Years | Antimanic Agents - therapeutic use | Quetiapine Fumarate | Antimanic Agents - economics | Bipolar Disorder - economics | Piperazines - therapeutic use | Delayed-Action Preparations - economics | Antimanic Agents - administration & dosage | Bipolar Disorder - mortality | Drug Therapy, Combination - economics | Bipolar Disorder - drug therapy | Dibenzothiazepines - administration & dosage | Antipsychotic Agents - administration & dosage | Health Care Costs | Quinolones - administration & dosage | Valproic Acid - administration & dosage | Lithium Compounds - therapeutic use | Triazines - administration & dosage | Cost-Benefit Analysis | Benzodiazepines - administration & dosage | Fees, Pharmaceutical | Triazines - economics | Benzodiazepines - therapeutic use | Lithium Compounds - administration & dosage | Valproic Acid - economics | antipsychotics; therapeutic use; aripiprazole; therapeutic use; bipolar-i-disorders; treatment; cost-utility; lamotrigine; therapeutic use; lithium; therapeutic use; olanzapine; therapeutic use; quetiapine; therapeutic use; valproate-semisodium; therapeutic use. | Economic aspects | Bipolar disorder | Dosage and administration | Research | Drug therapy | Quetiapine | Medical care, Cost of | Health care | Studies | Costs | Economic theory | Mathematical analysis | Medical treatment | Pharmaceuticals
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 23, pp. 2245 - 2254
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antimanic Agents - therapeutic use | Heart Defects, Congenital - chemically induced | Prevalence | Triazines - therapeutic use | Humans | Anticonvulsants - therapeutic use | Infant | Lithium Compounds - adverse effects | Bipolar Disorder - drug therapy | Pregnancy Trimester, First | Pregnancy Complications - drug therapy | Antidepressive Agents - therapeutic use | Pregnancy | Young Adult | Anticonvulsants - adverse effects | Lithium Compounds - therapeutic use | Heart Defects, Congenital - epidemiology | Adult | Female | Triazines - adverse effects | Antidepressive Agents - adverse effects | Antimanic Agents - adverse effects | Infant, Newborn | Cohort Studies | Heart failure | Lithium | Usage | Health aspects | Risk factors | Heart | Congenital diseases | Mental disorders | Bipolar disorder | Birth defects | Infants | Mood | Maternal & child health | Ventricle | Health risk assessment | Drug therapy | Heart diseases | Lamotrigine | Index Medicus | Abridged Index Medicus
Journal Article
Pharmacological reviews, ISSN 0031-6997, Volume 65, Issue 1, pp. 105 - 142
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Neuroprotective Agents - therapeutic use | Animals | Antimanic Agents - therapeutic use | Bipolar Disorder | Lithium Compounds - therapeutic use | Humans | Central Nervous System Diseases - drug therapy | Valproic Acid - therapeutic use | Index Medicus | Review
Journal Article